Skip to main content
Eye logoLink to Eye
. 2020 Dec 15;35(4):1286. doi: 10.1038/s41433-020-01351-7

Correction: Brolucizumab—early real-world experience: BREW study

Ashish Sharma 1,, Nilesh Kumar 1, Nikulaa Parachuri 1, Srinivas R Sadda 2, Giulia Corradetti 2, Jeffrey Heier 3, Adam T Chin 3,4, David Boyer 5, Pouya Dayani 5, Sruthi Arepalli 6, Peter Kaiser 6
PMCID: PMC8115258  PMID: 33323990

Correction to: Eye

10.1038/s41433-020-1111-x

Since online publication of this article, the authors became aware of two errors in the text of the manuscript:

  1. Page 1 Paragraph 1, an incorrect approval date was inserted. The correct sentence is provided below:

    Brolucizumab (Beovu, Novartis, Basel, Switzerland) is the newest anti-vascular endothelial growth factor (anti-VEGF) drug. lt was approved for the treatment of neovascular age-related macular degeneration (nAMD) by the US-FDA on October 7, 2019, followed by the European Commission’s approval for use in the European Union on February 13, 2020.

  2. Page 2 Paragraph 1, an incorrect percentage was provided. The correct sentence is provided below:

Pigment epithelial detachment (PED) was present in 31 eyes (73.8%) at baseline and resolved in 2 eyes (6.4%), was reduced in 13 eyes (41.9%\, and did not show any change in 16 eyes (51.6%) (Fig. 1).

The authors apologise for any inconvenience caused.

Footnotes

The original article can be found online at 10.1038/s41433-020-1111-x.


Articles from Eye are provided here courtesy of Nature Publishing Group

RESOURCES